Gilead Sciences (GILD) EBT (2009 - 2026)

Gilead Sciences (GILD) has reported EBT for 18 consecutive years, with $2.6 billion the latest figure, recorded in Q1 2026.

• EBT for Q1 2026 came in at $2.6 billion, up 56.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.7 billion (up 57.19% YoY), and the FY2025 annual result was $9.8 billion, up 1319.71% from the prior year.
• EBT was $2.6 billion for Q1 2026 at Gilead Sciences, up from $2.1 billion in the prior quarter.
• Over five years, EBT peaked at $3.6 billion in Q3 2025 and troughed at -$4.5 billion in Q1 2024.
• Average EBT over 5 years is $1.5 billion, with a median of $2.0 billion recorded in 2022.
• Year-over-year, EBT jumped 955.26% in 2023 and plunged 445.08% in 2024.
• Over 5 years, EBT stood at $2.0 billion in 2022, then declined by 18.61% to $1.7 billion in 2023, then soared by 31.09% to $2.2 billion in 2024, then dropped by 4.11% to $2.1 billion in 2025, then climbed by 24.16% to $2.6 billion in 2026.
• Per Business Quant data, the three most recent EBT figures were $2.6 billion in Q1 2026, $2.1 billion in Q4 2025, and $3.6 billion in Q3 2025.